AbbVie gets FDA nod for potential blockbuster Orilissa

The US Food and Drug Administration (FDA) has announced its approval of AbbVie's (NYSE: ABBV) Orilissa (elagolix) for moderate-to-severe endometriosis pain.

The drug, developed by AbbVie in conjunction with Neurocrine Biosciences (Nasdaq: NBIX) is the first new oral therapy to be approved in its indication for a decade.

"Endometriosis is often characterized by chronic pelvic pain that can impact women's daily activities," said Hugh Taylor, study investigator and chairman of the department of obstetrics, gynecology and reproductive sciences, Yale School of Medicine.